CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company, will present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO David Cory will deliver a company update on September 8, 2025 at 10:00 AM ET. The company, which focuses on developing therapies for organ transplant rejection and autoimmune diseases, will also conduct one-on-one meetings with investors during the conference.
CASI Pharmaceuticals (NASDAQ:CASI), una società biofarmaceutica in fase clinica, presenterà al prossimo H.C. Wainwright 27th Annual Global Investment Conference. Il CEO David Cory fornirà un aggiornamento sull'azienda il 8 settembre 2025 alle 10:00 ET. La società, che si concentra sullo sviluppo di terapie per il rigetto degli organi e le malattie autoimmuni, terrà anche incontri one-to-one con gli investitori durante la conferenza.
CASI Pharmaceuticals (NASDAQ:CASI), una compañía biofarmacéutica en fase clínica, presentará en la próxima H.C. Wainwright 27th Annual Global Investment Conference. El CEO David Cory ofrecerá una actualización de la compañía el 8 de septiembre de 2025 a las 10:00 ET. La empresa, que se centra en desarrollar terapias para el rechazo de órganos y las enfermedades autoinmunes, también mantendrá reuniones individuales con inversores durante la conferencia.
CASI Pharmaceuticals (NASDAQ:CASI)는 임상 단계의 바이오제약 회사로, 다가오는 H.C. Wainwright 27th Annual Global Investment Conference에서 발표합니다. CEO 데이비드 코리(David Cory)는 2025년 9월 8일 오전 10:00(동부 표준시)에 회사 현황을 보고할 예정입니다. 장기 이식 거부 반응 및 자가면역 질환 치료법 개발에 주력하는 이 회사는 회의 기간 동안 투자자들과의 일대일 미팅도 진행합니다.
CASI Pharmaceuticals (NASDAQ:CASI), une société biopharmaceutique en phase clinique, présentera lors de la prochaine H.C. Wainwright 27th Annual Global Investment Conference. Le PDG David Cory fera le point sur l'entreprise le 8 septembre 2025 à 10h00 ET. La société, qui se concentre sur le développement de traitements contre le rejet d'organes et les maladies auto-immunes, tiendra également des réunions individuelles avec des investisseurs pendant la conférence.
CASI Pharmaceuticals (NASDAQ:CASI), ein biopharmazeutisches Unternehmen in klinischer Phase, wird auf der kommenden H.C. Wainwright 27th Annual Global Investment Conference präsentieren. CEO David Cory wird am 8. September 2025 um 10:00 Uhr ET ein Unternehmensupdate geben. Das Unternehmen, das sich auf die Entwicklung von Therapien gegen Organabstoßung und Autoimmunerkrankungen spezialisiert hat, wird während der Konferenz außerdem Einzelgespräche mit Investoren führen.
- None.
- None.
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.
CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When is CASI Pharmaceuticals presenting at the H.C. Wainwright Conference?
Who will present CASI Pharmaceuticals' company update at the H.C. Wainwright Conference?
What therapeutic areas does CASI Pharmaceuticals focus on?
Will CASI Pharmaceuticals offer investor meetings at the H.C. Wainwright Conference?
